Quick Takeaways
- Redmile Group, LLC filed SCHEDULE 13G/A for Stoke Therapeutics, Inc. Common Stock, $0.0001 par value per share (STOK).
- Disclosed ownership: 8%.
- Date of event: 30 Jun 2025.
Redmile Group, LLC - 30 Jun 2025 SCHEDULE 13G/A Report for Stoke Therapeutics, Inc. Common Stock, $0.0001 par value per share (STOK)
- Filing Manager
- Redmile Group, LLC
- Reporting Manager
- Redmile Group, LLC
- Symbol
- STOK
- Shares outstanding
- 54,699,138 shares
- Disclosed Ownership
- 4,375,931 shares
- Ownership
- 8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 16:19:42 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Redmile Group, LLC disclosed 8% ownership in Stoke Therapeutics, Inc. Common Stock, $0.0001 par value per share (STOK) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Aug 2025, 16:19.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 8% | 4,375,931 | 0 | 4,375,931 | /s/ Jeremy C. Green | Managing Member | |
| Jeremy C. Green | 8% | 4,375,931 | 0 | 4,375,931 | /s/ Jeremy C. Green | Jeremy C. Green | |
| Redmile Biopharma Investments III, L.P. | 6.4% | 3,505,612 | 0 | 3,505,612 | /s/ Jeremy C. Green | Managing Member of Redmile Biopharma Investments III (GP), LLC, general partner of Redmile Biopharma Investments III, L.P. |